Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441115 · ClinicalTrials.gov registry record · Phase 1
ECI301 and Radiation for Advanced or Metastatic Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01441115: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01441115 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01441115, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
Background: \- ECI301 is a drug that may help make cancer cells more visible to the immune system after radiation. The drug may also help the immune system destroy the cancer at sites that have not received radiation therapy. Researchers want to study ECI301 in people with advanced cancer or cancer that has spread in the body (metastatic). Objectives: \- To test ECI301 with radiation therapy for advanced or metastatic cancer. Eligibility: \- People at least 18 years of age with either metastatic or advanced cancer that may benefit from radiation therapy. Design: * Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, and imaging studies. * All participants will have radiation therapy 5 days a week for 2 weeks. * They will have different doses of ECI301 to test its safety and effectiveness. ECI301 will be given in a vein during the second week of radiation therapy. Frequent blood tests and imaging studies will monitor the treatment. * After participants have ECI301, tumor samples may be taken from the site that had radiation and another site that did not have radiation. * Follow-up visits will include blood tests and imaging studies.
Interventions
- PROCEDURE Radiation Therapy
- DRUG ECI301
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-09-06 |
| Est. Completion | 2013-04-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441115
The ClinicalTrials.gov registry entry for NCT01441115 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT01441115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441115 about?
NCT01441115 is a clinical study titled "ECI301 and Radiation for Advanced or Metastatic Cancer". Background: \- ECI301 is a drug that may help make cancer cells more visible to the immune system after radiation. The drug may also help the immune system destroy the cancer at sites that have not received radiation therapy. Researchers want to study ECI301 in people with advanced cancer or cancer...
What is the current status of trial NCT01441115?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2011-09-06. Estimated completion is 2013-04-24.
What interventions are being tested in trial NCT01441115?
The interventions under investigation include: Radiation Therapy (PROCEDURE), ECI301 (DRUG).
Who is sponsoring clinical trial NCT01441115?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.